Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanofi Consumer Healthcare IndiaNSE:SANOFICONR -0.43%21 ROC (Joel Greenblatt) % is 1,251.53% as of Jun. 2026, which is 25% below its 10-year median of 1,677.59. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 981 Drug Manufacturers companies, Sanofi Consumer Healthcare India ranks better than 99.18% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Sanofi Consumer Healthcare India's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 1,251.53%.
The historical rank and industry rank for Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:SANOFICONR'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 844.51 Med: 1677.59 Max: 10975
Current: 844.51
During the past 3 years, Sanofi Consumer Healthcare India's highest ROC (Joel Greenblatt) % was 10975.00%. The lowest was 844.51%. And the median was 1677.59%.
NSE:SANOFICONR's ROC (Joel Greenblatt) % is ranked better than 99.18% of 981
companies
in the Drug Manufacturers industry
Industry Median: 10.75
vs NSE:SANOFICONR: 844.51
Sanofi Consumer Healthcare India (NSE:SANOFICONR) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanofi Consumer Healthcare India ROC (Joel Greenblatt) % Chart
NSE:SANOFICONR vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanofi Consumer Healthcare India ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % falls into.
Sanofi Consumer Healthcare India ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 1,251.53% mean?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a ROC (Joel Greenblatt) % of 1,251.53% as of Jun. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sanofi Consumer Healthcare India and its competitors. This is 25% below median its historical median of 1,677.59. Over the past decade, Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % has ranged from 844.51 to 10,975.00. According to the industry distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 981 companies in the Drug Manufacturers industry, placing it in the top 0.8%.
Is Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % too high?
Sanofi Consumer Healthcare India's current ROC (Joel Greenblatt) % of 1,251.53% is 25% below median its 10-year median of 1,677.59. Over the past 10 years, this metric has ranged from a low of 844.51 to a high of 10,975.00. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 10.75. Sanofi Consumer Healthcare India's value of 1,251.53% is 11542.1% above this industry median. Based on the distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sanofi Consumer Healthcare India ranks #8 out of 981 companies for ROC (Joel Greenblatt) %. This places Sanofi Consumer Healthcare India in the top 1% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 10.75. Sanofi Consumer Healthcare India's value of 1,251.53% is 11542.1% above this benchmark. Historically, Sanofi Consumer Healthcare India's own ROC (Joel Greenblatt) % has ranged from 844.51 to 10,975.00 over the past decade. While the company's 10-year median is 1,677.59 vs. the industry median of 10.75, Sanofi Consumer Healthcare India has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 10.75, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanofi Consumer Healthcare India's current ROC (Joel Greenblatt) % of 1,251.53% is 11542.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Sanofi Consumer Healthcare India and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 10.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanofi Consumer Healthcare India's current ROC (Joel Greenblatt) % is 1,251.53%, which is 25% below median its own 10-year median of 1,677.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current ROC (Joel Greenblatt) % of 1,251.53%. The current ROC (Joel Greenblatt) % is 1,251.53%, which is 25% below median its 10-year median of 1,677.59 and 11542.1% above the Drug Manufacturers industry median of 10.75. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current ROC (Joel Greenblatt) % is 1,251.53% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score
Get the complete analysis for NSE:SANOFICONR
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SANOFICONR has been successfully added to your 
